| Ms Roberta W Sposato, RPH | |
|
25 Wells St, Westerly, RI 02891 | |
| (401) 348-3450 | |
| (401) 348-3632 |
| Full Name | Ms Roberta W Sposato |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 25 Wells St, Westerly, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447322300 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 12619 (Ohio) | Secondary |
| 183500000X | Pharmacist | 4343 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Roberta W Sposato, RPH 18 Brookside Rd, Westerly, RI 02891 Ph: (401) 596-4320 | Ms Roberta W Sposato, RPH 25 Wells St, Westerly, RI 02891 Ph: (401) 348-3450 |
News Archive
Last June, President Obama announced the Materials Genome Initiative, an ambitious effort to assist American companies to develop advanced materials at twice the speed as currently possible and at a fraction of the cost.
Aetna today announced the results of a study of health care claims and utilization for members in its Aetna HealthFund® consumer-directed plans. The study of two million Aetna members shows sustained savings over time and increased member engagement in their health.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.
According to an annual survey released Tuesday by the George Institute for International Health that looks at research and development (R&D) funding of diseases that affect the developing world, the U.S. government in 2008 "remained the single biggest contributor as it again provided almost half of the total funding but the report notes developing countries like Brazil [and] India ... were becoming a growing force," AAP/Sydney Morning Herald reports (Rose, 12/15).
A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.
› Verified 1 days ago
Loreen Cimalore, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 150 Granite St, Westerly, RI 02891 Phone: 401-348-7060 Fax: 401-348-6429 | |
Jennifer Aimee Felix, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 151 Franklin St, Westerly, RI 02891 Phone: 401-596-8187 Fax: 401-596-8187 | |
Dr. Rebecca Ann Corvese, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 170 Granite St, Westerly, RI 02891 Phone: 401-596-2734 | |
Dr. Brian James Musiak, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 25 Wells St, Westerly, RI 02891 Phone: 401-348-3450 Fax: 401-348-3632 | |
Amy Dolahan, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 106 Main St, Westerly, RI 02891 Phone: 401-596-0277 | |
Timothy A Lee, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 170 Granite St, Westerly, RI 02891 Phone: 401-596-2734 Fax: 401-596-8521 | |
Mrs. Linda Brocato, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 25 Wells St, Westerly Hospital, Westerly, RI 02891 Phone: 401-348-3351 Fax: 401-348-3632 |